A5108043334- Lung Cancer Treatments and Mutations
- HER2/EGFR in Cancer Research
- Cancer-related molecular mechanisms research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cytokine Signaling Pathways and Interactions
Shanghai Jiao Tong University
2024
Shanghai Chest Hospital
2024
First Affiliated Hospital of GuangXi Medical University
2023
Guangxi Medical University
2023
To evaluate the impact of sequential (first- to third-generation) epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment on top-corrected QT interval (top-QTc) in non-small cell lung cancer (NSCLC) patients. We retrospectively reviewed medical records NSCLC patients undergoing EGFR-TKI at Shanghai Chest Hospital between October 2016 and August 2021. The heart rate (HR), top-QT interval, top-QTc their ECGs were extracted from institutional database analyzed. Logistic...
To develop optimal personalized therapy for lung adenocarcinoma (LUAD), potential biomarkers associated with the prognosis are urgently needed. It is unclear what role T Cell Leukemia Homeobox 1 (TLX1) plays in LUAD.